Context Therapeutics (NASDAQ:CNTX – Get Free Report) and Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.
Institutional & Insider Ownership
14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 2.8% of Context Therapeutics shares are held by company insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Context Therapeutics and Alaunos Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Context Therapeutics | N/A | N/A | -$23.96 million | ($0.31) | -2.00 |
| Alaunos Therapeutics | $11,000.00 | 459.20 | -$35.14 million | N/A | N/A |
Context Therapeutics has higher earnings, but lower revenue than Alaunos Therapeutics.
Volatility and Risk
Context Therapeutics has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500. Comparatively, Alaunos Therapeutics has a beta of -1.08, suggesting that its share price is 208% less volatile than the S&P 500.
Profitability
This table compares Context Therapeutics and Alaunos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Context Therapeutics | N/A | -58.76% | -55.80% |
| Alaunos Therapeutics | N/A | -267.77% | -209.18% |
Analyst Recommendations
This is a summary of current ratings and price targets for Context Therapeutics and Alaunos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Context Therapeutics | 0 | 0 | 4 | 1 | 3.20 |
| Alaunos Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Context Therapeutics currently has a consensus price target of $6.00, indicating a potential upside of 867.27%. Given Context Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Context Therapeutics is more favorable than Alaunos Therapeutics.
Summary
Context Therapeutics beats Alaunos Therapeutics on 8 of the 11 factors compared between the two stocks.
About Context Therapeutics
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
About Alaunos Therapeutics
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
